Personalized Dosing Strategies

Personalized dosing strategies are systematic ways of adjusting the dose of a medicine to the characteristics of the individual patient, so that exposure is more likely to fall within an effective and tolerable range. They combine genetic information, measured drug concentrations, organ function, and pharmacokinetic models to move beyond fixed, one-size-fits-all dosing. This topic covers the principles behind those strategies.

Definition

Personalized dosing strategies are methods for tailoring a drug's dose to individual factors — including genotype, measured drug concentration, organ function, body size, and concomitant therapy — with the aim of achieving target drug exposure or effect more reliably than fixed dosing.

Scope

The entry covers the rationale for dose individualization, the main approaches — genotype-guided dosing, therapeutic drug monitoring, and model-informed precision dosing — and the patient and drug characteristics that justify them. It is a conceptual reference and deliberately gives no specific doses, targets, or treatment instructions.

Core questions

• When does fixed dosing fail to deliver consistent exposure?
• How do genotype, drug concentration, and organ function inform dose adjustment?
• What distinguishes therapeutic drug monitoring from model-informed precision dosing?
• For which drugs is individualized dosing most valuable?

Key concepts

• Narrow therapeutic index
• Target concentration and exposure-response relationship
• Genotype-guided dosing
• Therapeutic drug monitoring (TDM)
• Model-informed precision dosing
• Covariates: organ function, body size, age
• Loading versus maintenance dose individualization

Mechanisms

Dose individualization addresses variability in the relationship between dose, drug exposure, and effect. Three complementary approaches are common. Genotype-guided dosing uses pharmacogenetic information — for example, variants affecting a metabolizing enzyme or drug target — to anticipate atypical exposure before treatment begins. Therapeutic drug monitoring measures actual drug concentrations during treatment and adjusts the dose toward a target range, which is most useful for drugs with a narrow therapeutic index and a defined concentration-response relationship. Model-informed precision dosing combines population pharmacokinetic models with individual covariates and, where available, measured concentrations to predict an individualized dose. These approaches can be layered, with genotype informing an initial estimate and monitoring refining it (Evans & McLeod, 2003; International Warfarin Pharmacogenetics Consortium, 2009).

Clinical relevance

Personalized dosing is a core concern of clinical pharmacology because variable exposure underlies both treatment failure and dose-related toxicity for many drugs. This entry explains the principles for reference and education; it does not provide dosing values, targets, or individualized treatment advice, all of which require validated guidelines and clinical judgement.

Epidemiology

Individualized dosing is especially relevant for drugs with a narrow therapeutic index and high inter-individual variability, such as certain anticoagulants, immunosuppressants, antimicrobials, and chemotherapeutic agents, where a substantial fraction of patients would fall outside the desired exposure range on a fixed dose (Evans & McLeod, 2003).

Evidence & guidelines

Several gene-drug dosing approaches are codified in peer-reviewed guidelines; for example, the Clinical Pharmacogenetics Implementation Consortium has issued guidance on pharmacogenetics-guided warfarin dosing and on CYP2C9 in relation to certain analgesics, and the International Warfarin Pharmacogenetics Consortium derived a dosing algorithm combining clinical and genetic data (Johnson et al., 2017; International Warfarin Pharmacogenetics Consortium, 2009; Theken et al., 2020).

History

Therapeutic drug monitoring developed in the latter half of the twentieth century alongside the ability to assay drug concentrations. The integration of pharmacogenetics into dosing — exemplified by warfarin algorithms combining clinical and genetic predictors — and the later emergence of model-informed precision dosing extended individualization from measured concentrations to predictive, covariate-based methods.

Debates

Does genotype-guided initial dosing improve outcomes over standard care?

For some drugs, such as warfarin, trials of genotype-guided initiation have shown mixed results on hard clinical endpoints, leaving debate over how much pre-treatment genetic information adds beyond careful clinical dosing and monitoring.

Key figures

• Julie Johnson
• William Evans
• Howard McLeod
• Kelly Caudle

Seminal works

• iwpc-2009
• johnson-2017
• evans-mcleod-2003

Frequently asked questions

What is therapeutic drug monitoring?

It is the practice of measuring drug concentrations in a patient during treatment and using those measurements to adjust the dose toward a target range, used mainly for drugs with a narrow margin between effective and toxic exposure.

Is genotype-guided dosing always better than standard dosing?

Not necessarily. Its value depends on the drug and the strength of evidence; for some drugs it improves prediction of exposure, while for others trials have not consistently shown better clinical outcomes than careful conventional dosing with monitoring.